Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
1(20%)
Results Posted
150%(3 trials)
Terminated
1(20%)

Phase Distribution

Ph not_applicable
3
60%
Ph phase_2
1
20%
Ph phase_4
1
20%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
1(20.0%)
Phase 4Post-market surveillance
1(20.0%)
N/ANon-phased studies
3(60.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(2)
Terminated(1)
Other(1)

Detailed Status

Completed2
Active, not recruiting1
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (20.0%)
Phase 41 (20.0%)
N/A3 (60.0%)

Trials by Status

active_not_recruiting120%
terminated120%
unknown120%
completed240%

Recent Activity

1 active trials
Showing 5 of 5
active_not_recruitingphase_2

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

NCT02978625
terminatednot_applicable

Positron Emission Tomography Imaging Using Copper Cu 64 TP3805 in Patients With Breast Cancer

NCT02810873
completednot_applicable

Positron Emission Mammography and Standard Mammography in Women at High Risk of Breast Cancer

NCT00896649
completednot_applicable

Staging of Axillary Lymph Nodes Using the PEM Flex Solo II Pet Scanner in Patients With Breast Cancer

NCT01011946
unknownphase_4

Study the Role of Positron Emission Mammography in Pre-surgical Planning for Breast Cancer

NCT00484614

Clinical Trials (5)

Showing 5 of 5 trials
NCT02978625Phase 2

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

Active Not Recruiting
NCT02810873Not Applicable

Positron Emission Tomography Imaging Using Copper Cu 64 TP3805 in Patients With Breast Cancer

Terminated
NCT00896649Not Applicable

Positron Emission Mammography and Standard Mammography in Women at High Risk of Breast Cancer

Completed
NCT01011946Not Applicable

Staging of Axillary Lymph Nodes Using the PEM Flex Solo II Pet Scanner in Patients With Breast Cancer

Completed
NCT00484614Phase 4

Study the Role of Positron Emission Mammography in Pre-surgical Planning for Breast Cancer

Unknown

All 5 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
5